profit from every $100 of sales.
$0$100
AgomAb Therapeutics
$6.99+0.00% today
-52.3% since Feb 6, 26
1-year low $6.721-year high $17.82
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What AgomAb Therapeutics sold, what it kept, and what it did with the cash.
Sales went from €0 in 2022 to €0 in 2025, with -€62.5 million of profit last year.
SalesProfit
AgomAb Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| AgomAb Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads AgomAb Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -23 | -31 | -48 | -59 | |
| -11 | -12 | -46 | -62 | |
| -8 | -11 | -46 | -63 | |
| -0.22 | -0.31 | -1.28 | – | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 101 | 171 | 206 | 154 |
| Cash | 28 | 122 | 171 | 86 |
| Total debt | 0 | 2 | 2 | 1 |
| Total liabilities | 35 | 20 | 18 | 23 |
| 66 | 151 | 188 | 131 | |
| 36 | 36 | 36 | – | |
| -12.8% | -6.2% | -19.2% | -37.4% | |
| -12.3% | -7.5% | -24.6% | -47.8% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -19 | -25 | -47 | -52 | |
| – | – | 1 | 0 | |
| -19 | -25 | -48 | -52 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 2 | 1 | 5 |
Valuation
- –
- –
- –
- 0.0×
- –
- –
- –
- –
- -17.4%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- –
- 0.0%
- 0.0%
- 0.0%
- –
Growth
- –
- –
- –
- –
- +0.0%
Financial health
- 0.0×
- 0.00
- 0.0%
- -716.7×
- –
- –
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 33%of 958
Bottom 21%of 888
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 23, 2026 | -0.56 | -0.52 | −9.1% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
32No pass
Benjamin Graham
53No pass
Philip Fisher
39No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
29No pass
Terry Smith
26No pass
Questions about AgomAb Therapeutics
Is AgomAb Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the AgomAb Therapeutics AI analysis
What does AgomAb Therapeutics do?
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. It is in Biotechnology.
Does AgomAb Therapeutics pay a dividend?
No. AgomAb Therapeutics does not pay a dividend at the moment.
Is AgomAb Therapeutics stock halal?
Questionable. AgomAb Therapeutics sits in a grey zone: short-term investments may earn interest; type not reported. How we check
Who are AgomAb Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with AgomAb Therapeutics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.